DJIA 18,080.14 21.45 0.12%
NASDAQ 5,092.09 36.02 0.71%
S&P 500 2,117.69 4.76 0.23%
market minute promo

Merck & Co., Inc. (NYSE: MRK)



company name or ticker
Company Photos
(Click to zoom)

OncoSec Medical Has A Promising Technology

Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?

Gilead Sciences has become a battleground stock due to the uncertainty surrounding the future of the hep C market. Here is a look at why the bears might be right in their assessment of this top biotech stock.

Merck: Buyback Plan Not As Impressive As It Appears

Out of 12 Big Pharma Stocks, This is the 1 You Can Confidently Hold for the Next 10 Years

Big Pharma stocks often have deep product pipelines, substantial cash flow, and healthy dividends, but they are far from created equal. With patent expirations taking their toll, this would appear to be the one Big Pharma stock you can trust over the next decade.

Immune Design Starts Dosing Patients in CMB305 Study - Analyst Blog

Is This Tiny Biotech Still a Buy at All-Time Highs?

Repligen may not be on your watchlist, but it has been (very) good to investors in recent years. Will the ride continue?

Merck in $10B Buyback; Keytruda Tops Melanoma Study - Analyst Blog

Ligand Pharmaceuticals: Biotech's Jack Of All Trades

Dow Movers: MSFT, MRK

How Gilead And AbbVie Closed The HCV Door On Merck